Clinical trial
Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)
NCT02585479 is registered in ClinicalTrials.gov with Guangxi Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)
- Lead sponsor
- Guangxi Medical University
- Phase
- Phase 2/3
- Overall status
- Withdrawn
- Start date
- October 31, 2015
- Completion date
- October 31, 2017
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma